

To examine differences between experimental conditions, we will conduct inferential statistical tests such as analysis of variance. With the sample

size described in the following table, we will have sufficient power to detect small-to-medium sized effects in the main study.

FDA estimates the burden of this collection of information as follows:

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN <sup>1</sup>

Activity	Number of respondents	Number of responses per respondent	Total annual respondents	Average burden per response	Total hours
Pretest 1 screener completes (assumes 10% eligible)	4,150	1	4,150	0.08 (5 minutes) .....	332
Pretest 2 screener completes (assumes 10% eligible)	4,150	1	4,150	0.08 (5 minutes) .....	332
Number of main study screener completes (assumes 10% eligible).	620	1	620	0.08 (5 minutes) .....	50
Pretest 1 completes .....	420	1	420	2 .....	840
Pretest 2 completes .....	420	1	420	2 .....	840
Number of completes, main study .....	620	1	620	2 .....	1240
Total .....					3,634

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

## References

The following references have been placed on display in the Division of Dockets Management (see **ADDRESSES**) and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday, and are available electronically at <http://www.regulations.gov>.

1. Singh, S. N., D. Linville, and A. Sukhdial, "Enhancing the Efficacy of Split Thirty-Second Television Commercials: An Encoding Variability Application," *Journal of Advertising*, 24, pp. 13–23 (1995).
2. Haugtvedt, C. P., et al., "Advertising Repetition and Variation Strategies: Implications for Understanding Attitude Strength," *Journal of Consumer Research*, 21, pp. 176–189 (1994).
3. Naples, M. J., "Effective Frequency: Then and Now," *Journal of Advertising Research*, 37, pp. 7–12 (1997).

Dated: November 5, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014–26698 Filed 11–10–14; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2013–F–1539]

#### DSM Nutritional Products; Food Additive Petition (Animal Use); Ethoxyquin; Environmental Assessment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of an environmental

assessment filed by DSM Nutritional Products in support of their petition proposing that the food additive regulations be amended to provide for the safe use of ethoxyquin in vitamin D formulations, including 25-hydroxyvitamin D<sub>3</sub>, used in animal food.

**ADDRESSES:** Submit electronic comments to: <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Isabel W. Pocurull, Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–453–6853.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of December 23, 2013 (78 FR 77384) FDA published notice that a food additive petition (FAP) had been filed by DSM Nutritional Products, 45 Waterview Blvd., Parsippany, NJ 07054. The petition (FAP 2276) proposes to amend Title 21 of the Code of Federal Regulations (CFR) in part 573 *Food Additives Permitted in Feed and Drinking Water of Animals* (21 CFR part 573) to provide for the safe use of ethoxyquin as a chemical preservative in vitamin D formulations, including 25-hydroxyvitamin D<sub>3</sub>, used in animal food. In that document, FDA noted that the petitioner had requested a categorical exclusion from preparing an environmental assessment or environmental impact statement under 21 CFR 25.32(k).

Upon further review and request by FDA, the petitioner has filed an environmental assessment. To encourage public participation consistent with regulations issued under

the National Environmental Policy Act (40 CFR 1501.4(b)), the Agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Division of Dockets Management (see **ADDRESSES**) for public review and comment.

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) electronic or written comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the Agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the Agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.51(b).

Dated: November 6, 2014.

**Bernadette Dunham,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 2014–26709 Filed 11–10–14; 8:45 am]

**BILLING CODE 4164–01–P**